• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    UK Pharmacovigilance Market

    ID: MRFR/Pharma/49690-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    UK Pharmacovigilance Market Research Report By Service Type (Adverse Event Reporting, Risk Assessment, Data Mining, Pharmacovigilance Consulting), By Deployment Mode (Cloud-Based, On-Premise), By Source (Spontaneous Reporting, Literature Reports, Scheduled Reporting), and By End-user (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    UK Pharmacovigilance Market Research Report- Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    UK Pharmacovigilance Market Summary

    The United Kingdom UK Pharmacovigilance market is projected to grow significantly over the next decade.

    Key Market Trends & Highlights

    UK Pharmacovigilance Key Trends and Highlights

    • The market is valued at 400 USD Million in 2024 and is expected to reach 900 USD Million by 2035.
    • The compound annual growth rate (CAGR) for the market is estimated at 7.65% from 2025 to 2035.
    • This growth trajectory indicates a robust expansion in the pharmacovigilance sector within the UK.
    • Growing adoption of advanced data analytics due to increasing regulatory requirements is a major market driver.

    Market Size & Forecast

    2024 Market Size 400 (USD Million)
    2035 Market Size 900 (USD Million)
    CAGR (2025-2035) 7.65%

    Major Players

    Biogen, Pfizer, Amgen, Vertex Pharmaceuticals, Merck, UCB, GlaxoSmithKline, Roche, Bristol-Myers Squibb, AstraZeneca, Takeda, Johnson & Johnson, AbbVie, Sanofi, Novartis

    UK Pharmacovigilance Market Trends

    The necessity for thorough drug safety monitoring and growing regulatory scrutiny are driving significant trends in the UK pharmacovigilance market. The significance of post-marketing surveillance is being emphasised by the UK government through organisations such as the Medicines and Healthcare Products Regulatory Agency (MHRA).

    This is a reaction to the public's desire for more openness in healthcare and the rising frequency of drug-related side effects. Additionally, the method pharmacovigilance is carried out is changing due to the incorporation of cutting-edge technology like artificial intelligence and data analytics, which allow for quicker signal detection and improved risk management.

    Partnerships between technology businesses and pharmaceutical companies are exploring opportunities in the UK market by improving the effectiveness of data collecting and adverse event reporting procedures.

    Real-time data analysis is becoming increasingly popular since it provides instant insight into drug safety profiles. Because of the UK's dedication to patient safety, more money is being spent on pharmacovigilance experts' training and development, which enhances their skill sets and knowledge base in this area.

    In pharmacovigilance, there has been a recent movement in emphasis towards patient-centered approaches, where patients' experiences and feedback are increasingly acknowledged as being crucial to safety assessments. The significance of patient participation in medication safety monitoring is highlighted by this trend.

    Furthermore, new avenues for reporting adverse occurrences are being created by the increasing use of digital health solutions, which is consistent with the larger trend of increasing patient involvement in their own healthcare management.

    All things considered, these changes point to a gradual change in the UK pharmacovigilance market, encouraging a more proactive and comprehensive approach to medication safety.

    UK Pharmacovigilance Market Drivers

    Market Segment Insights

    Get more detailed insights about UK Pharmacovigilance Market Research Report- Forecast to 2035

    Regional Insights

    Key Players and Competitive Insights

    The competitive insights of the UK Pharmacovigilance Market reveal a dynamic landscape characterized by regulatory challenges, evolving technologies, and increasing demands for safety monitoring. The market is primarily driven by the need to ensure drug safety and compliance with stringent regulations set forth by regulatory bodies.

    As the emphasis on patient safety remains a priority, pharmaceutical companies and service providers are continually adapting their strategies and operational frameworks to meet the complex requirements of pharmacovigilance. New entrants and established players alike are focusing on advanced data collection, analysis, and reporting methodologies to thrive in this competitive environment.

    The influence of digital health technologies and big data analytics is rapidly transforming traditional pharmacovigilance practices, leading to more efficient monitoring processes that are also cost-effective. Overall, the UK market is witnessing heightened competition with firms striving to enhance service quality and operational efficiency in the realm of drug safety.

    In the context of the UK Pharmacovigilance Market, Biogen is recognized for its significant presence, driven by a robust pipeline of innovative therapies and its commitment to maintaining high standards of safety and efficacy.

    The company's strengths lie in its strategic approach to monitoring adverse drug reactions and implementing comprehensive risk management plans. By leveraging cutting-edge technologies, Biogen has enhanced its reporting capabilities and data management processes, thus optimizing pharmacovigilance operations.

    Its established relationships with regulatory authorities in the UK further enhance its market standing, while the focus on continual learning from safety data allows Biogen to adapt quickly to emerging safety signals, ensuring that their pharmacovigilance practices remain aligned with the latest regulatory expectations.

    Pfizer holds a strong position within the UK Pharmacovigilance Market, characterized by an extensive portfolio of key products and services. The company has developed a robust pharmacovigilance infrastructure that focuses on proactive safety monitoring and risk management, which is vital for maintaining the safety profile of its diverse range of medications.

    Pfizer's strengths lie in its innovative use of technology and data-driven approaches, which enhance the efficiency and effectiveness of its pharmacovigilance operations. The organization has been involved in strategic mergers and acquisitions that have further bolstered its capabilities and market presence in the UK.

    These investments have allowed Pfizer to integrate advanced systems for adverse event reporting and analysis, fostering a culture of safety that is essential for the sustainability of its business. The company's commitment to transparency and collaboration with health authorities reflects its dedication to drug safety, positioning it as a leader in the UK pharmacovigilance space.

    Key Companies in the UK Pharmacovigilance Market market include

    Industry Developments

    The UK Pharmacovigilance Market has seen significant developments recently, particularly regarding advancements in regulatory frameworks and technological integration. Companies like AstraZeneca and GlaxoSmithKline are enhancing their pharmacovigilance systems to comply with the evolving regulatory environment and harnessing data analytics for risk management.

    As of September 2023, the MHRA introduced a streamlined approach to reporting adverse drug reactions, aiming to improve drug safety monitoring. In terms of market dynamics, there has been a notable growth in the market valuation of major players such as Pfizer and Biogen as they expand their pharmacovigilance capabilities in response to increasing market demands and stringent regulations.

    Recent merger activities are also noteworthy; for instance, in July 2023, Bristol-Myers Squibb announced its acquisition of a smaller biotech firm to enhance its pharmacovigilance operations. Similar movements in acquisitions, such as Johnson and Johnson's strategic partnerships, are aimed at improving their pharmacovigilance efficiencies.

    Over the past few years, especially post-Brexit, the UK has adapted its regulatory policies, reinforcing its commitment to ensure the safety and efficacy of medications available to the public, ultimately positioning itself as a robust market in pharmacovigilance.

    Market Segmentation

    Pharmacovigilance Market Source Outlook

    • Spontaneous Reporting
    • Literature Reports
    • Scheduled Reporting

    Pharmacovigilance Market End-user Outlook

    • Pharmaceutical Companies
    • Biotechnology Companies
    • Contract Research Organizations

    Pharmacovigilance Market Service Type Outlook

    • Adverse Event Reporting
    • Risk Assessment
    • Data Mining
    • Pharmacovigilance Consulting

    Pharmacovigilance Market Deployment Mode Outlook

    • Cloud-Based
    • On-Premise

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 335.25(USD Million)
    MARKET SIZE 2024 400.0(USD Million)
    MARKET SIZE 2035 900.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 7.651% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Biogen, Pfizer, Amgen, Vertex Pharmaceuticals, Merck, UCB, GlaxoSmithKline, Roche, BristolMyers Squibb, AstraZeneca, Takeda, Johnson & Johnson, AbbVie, Sanofi, Novartis
    SEGMENTS COVERED Service Type, Deployment Mode, Source, End User
    KEY MARKET OPPORTUNITIES Regulatory compliance advancements, Integration of AI technologies, Growing drug development pipelines, Increased demand for patient safety, Expansion of real-world evidence studies
    KEY MARKET DYNAMICS Regulatory compliance requirements, Advancements in technology, Increased drug safety concerns, Growing patient-centric approaches, Rising pharmacovigilance outsourcing
    COUNTRIES COVERED UK

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the projected market size of the UK Pharmacovigilance Market in 2024?

    The UK Pharmacovigilance Market is expected to be valued at 400.0 million USD in 2024.

    What will be the expected market size of the UK Pharmacovigilance Market by 2035?

    By 2035, the UK Pharmacovigilance Market is projected to reach 900.0 million USD.

    What is the expected compound annual growth rate (CAGR) of the UK Pharmacovigilance Market from 2025 to 2035?

    The expected CAGR for the UK Pharmacovigilance Market from 2025 to 2035 is 7.651%.

    Which service type will hold the largest market share in the UK Pharmacovigilance Market by 2035?

    Adverse Event Reporting is anticipated to hold the largest market share, valued at 270.0 million USD by 2035.

    What is the market share of Risk Assessment services in 2024?

    Risk Assessment services are valued at 90.0 million USD in the UK Pharmacovigilance Market in 2024.

    Who are the major players in the UK Pharmacovigilance Market?

    Key players include Biogen, Pfizer, Amgen, Merck, GlaxoSmithKline, Johnson & Johnson, and others.

    What will be the market size for Data Mining services in the UK Pharmacovigilance Market by 2035?

    The market size for Data Mining services is expected to reach 180.0 million USD by 2035.

    What is the anticipated market size for Pharmacovigilance Consulting in 2024?

    Pharmacovigilance Consulting is valued at approximately 110.0 million USD in 2024.

    What growth opportunities exist in the UK Pharmacovigilance Market?

    The growth opportunities lie in increasing regulatory demands and a heightened focus on patient safety.

    How might global conflicts impact the UK Pharmacovigilance Market?

    Global conflicts may affect supply chains and regulatory compliance, impacting market dynamics.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. UK Pharmacovigilance Market, BY Service Type (USD Million)
    45. Adverse Event Reporting
    46. Risk Assessment
    47. Data Mining
    48. Pharmacovigilance Consulting
    49. UK Pharmacovigilance Market, BY Deployment Mode (USD Million)
    50. Cloud-Based
    51. On-Premise
    52. UK Pharmacovigilance Market, BY Source (USD Million)
    53. Spontaneous Reporting
    54. Literature Reports
    55. Scheduled Reporting
    56. UK Pharmacovigilance Market, BY End User (USD Million)
    57. Pharmaceutical Companies
    58. Biotechnology Companies
    59. Contract Research Organizations
    60. Competitive Landscape
    61. Overview
    62. Competitive Analysis
    63. Market share Analysis
    64. Major Growth Strategy in the Pharmacovigilance Market
    65. Competitive Benchmarking
    66. Leading Players in Terms of Number of Developments in the Pharmacovigilance Market
    67. Key developments and growth strategies
    68. New Product Launch/Service Deployment
    69. Merger & Acquisitions
    70. Joint Ventures
    71. Major Players Financial Matrix
    72. Sales and Operating Income
    73. Major Players R&D Expenditure. 2023
    74. Company Profiles
    75. Biogen
    76. Financial Overview
    77. Products Offered
    78. Key Developments
    79. SWOT Analysis
    80. Key Strategies
    81. Pfizer
    82. Financial Overview
    83. Products Offered
    84. Key Developments
    85. SWOT Analysis
    86. Key Strategies
    87. Amgen
    88. Financial Overview
    89. Products Offered
    90. Key Developments
    91. SWOT Analysis
    92. Key Strategies
    93. Vertex Pharmaceuticals
    94. Financial Overview
    95. Products Offered
    96. Key Developments
    97. SWOT Analysis
    98. Key Strategies
    99. Merck
    100. Financial Overview
    101. Products Offered
    102. Key Developments
    103. SWOT Analysis
    104. Key Strategies
    105. UCB
    106. Financial Overview
    107. Products Offered
    108. Key Developments
    109. SWOT Analysis
    110. Key Strategies
    111. GlaxoSmithKline
    112. Financial Overview
    113. Products Offered
    114. Key Developments
    115. SWOT Analysis
    116. Key Strategies
    117. Roche
    118. Financial Overview
    119. Products Offered
    120. Key Developments
    121. SWOT Analysis
    122. Key Strategies
    123. BristolMyers Squibb
    124. Financial Overview
    125. Products Offered
    126. Key Developments
    127. SWOT Analysis
    128. Key Strategies
    129. AstraZeneca
    130. Financial Overview
    131. Products Offered
    132. Key Developments
    133. SWOT Analysis
    134. Key Strategies
    135. Takeda
    136. Financial Overview
    137. Products Offered
    138. Key Developments
    139. SWOT Analysis
    140. Key Strategies
    141. Johnson & Johnson
    142. Financial Overview
    143. Products Offered
    144. Key Developments
    145. SWOT Analysis
    146. Key Strategies
    147. AbbVie
    148. Financial Overview
    149. Products Offered
    150. Key Developments
    151. SWOT Analysis
    152. Key Strategies
    153. Sanofi
    154. Financial Overview
    155. Products Offered
    156. Key Developments
    157. SWOT Analysis
    158. Key Strategies
    159. Novartis
    160. Financial Overview
    161. Products Offered
    162. Key Developments
    163. SWOT Analysis
    164. Key Strategies
    165. References
    166. Related Reports
    167. UK Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY SERVICE TYPE, 2019-2035 (USD Billions)
    168. UK Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY DEPLOYMENT MODE, 2019-2035 (USD Billions)
    169. UK Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY SOURCE, 2019-2035 (USD Billions)
    170. UK Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    171. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    172. ACQUISITION/PARTNERSHIP
    173. MARKET SYNOPSIS
    174. UK PHARMACOVIGILANCE MARKET ANALYSIS BY SERVICE TYPE
    175. UK PHARMACOVIGILANCE MARKET ANALYSIS BY DEPLOYMENT MODE
    176. UK PHARMACOVIGILANCE MARKET ANALYSIS BY SOURCE
    177. UK PHARMACOVIGILANCE MARKET ANALYSIS BY END USER
    178. KEY BUYING CRITERIA OF PHARMACOVIGILANCE MARKET
    179. RESEARCH PROCESS OF MRFR
    180. DRO ANALYSIS OF PHARMACOVIGILANCE MARKET
    181. DRIVERS IMPACT ANALYSIS: PHARMACOVIGILANCE MARKET
    182. RESTRAINTS IMPACT ANALYSIS: PHARMACOVIGILANCE MARKET
    183. SUPPLY / VALUE CHAIN: PHARMACOVIGILANCE MARKET
    184. PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2025 (% SHARE)
    185. PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2019 TO 2035 (USD Billions)
    186. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2025 (% SHARE)
    187. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2019 TO 2035 (USD Billions)
    188. PHARMACOVIGILANCE MARKET, BY SOURCE, 2025 (% SHARE)
    189. PHARMACOVIGILANCE MARKET, BY SOURCE, 2019 TO 2035 (USD Billions)
    190. PHARMACOVIGILANCE MARKET, BY END USER, 2025 (% SHARE)
    191. PHARMACOVIGILANCE MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    192. BENCHMARKING OF MAJOR COMPETITORS

    UK Pharmacovigilance Market Segmentation

     

     

     

    • Pharmacovigilance Market By Service Type (USD Million, 2019-2035)

      • Adverse Event Reporting
      • Risk Assessment
      • Data Mining
      • Pharmacovigilance Consulting

     

    • Pharmacovigilance Market By Deployment Mode (USD Million, 2019-2035)

      • Cloud-Based
      • On-Premise

     

    • Pharmacovigilance Market By Source (USD Million, 2019-2035)

      • Spontaneous Reporting
      • Literature Reports
      • Scheduled Reporting

     

    • Pharmacovigilance Market By End User (USD Million, 2019-2035)

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Contract Research Organizations

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials